ABSTRACT
Mycosis fungoides (MF) is the most common primary cutaneous T-cell lymphoma (CTCL) with its etiology not yet fully understood. Interleukin (IL)-35 is an inhibitory cytokine that belongs to the IL-12 family. Elevated IL-35 in the plasma and the tumor microenvironment increases tumorigenesis and indicates poor prognosis in different types of malignancies. The objective of this study is to estimate the expression levels of IL-35 in tissue and serum of MF patients versus healthy controls. This case-control study included 35 patients with patch, plaque, and tumor MF as well as 30 healthy controls. Patients were fully assessed, and serum samples and lesional skin biopsies were taken prior to starting treatment. The IL-35 levels were measured in both serum and tissue biopsies by ELISA technique. Both tissue and serum IL-35 levels were significantly higher in MF patients than in controls (P < 0.001) and tissue IL-35 was significantly higher than serum IL-35 in MF patients (P < 0.001). Tissue IL-35 was significantly higher in female patients and patients with recurrent MF compared to male patients and those without recurrent disease (P < 0.001). Since both tissue and serum IL-35 levels are increased in MF, IL-35 is suggested to have a possible role in MF pathogenesis. IL-35 can be a useful diagnostic marker for MF. Tissue IL-35 can also be an indicator of disease recurrence.
Subject(s)
Interleukins , Mycosis Fungoides , Skin Neoplasms , Humans , Mycosis Fungoides/blood , Mycosis Fungoides/diagnosis , Mycosis Fungoides/pathology , Interleukins/blood , Interleukins/metabolism , Female , Male , Case-Control Studies , Middle Aged , Skin Neoplasms/blood , Skin Neoplasms/diagnosis , Skin Neoplasms/pathology , Adult , Skin/pathology , Skin/metabolism , Aged , Biopsy , Biomarkers, Tumor/bloodABSTRACT
BACKGROUND: Noncultured Epidermal Cell Suspension (NCECS) is a surgical modality used in treating stable vitiligo. Trypsinization of the epidermis may be done either at 4°C overnight (cold) or at 37°C for 30 to 50 minutes (warm). Recently, trypsinization was done at room temperature (25°C) in an in vitro trial. OBJECTIVE: To compare different trypsinization techniques in NCECS regarding cell viability and clinical outcome. METHODS: This comparative multicenter study was conducted on 20 patients with stable nonsegmental vitiligo. In each patient, 3, nonacral vitiligo lesions were randomly assigned for treatment by NCECS prepared by warm, room temperature, and cold trypsinization techniques, respectively. A perilesional biopsy was taken from each of the 3 treated lesions as an objective measure of disease stability. After transplantation, all patients received narrow-band ultraviolet B twice weekly for 6 months. Cell viability was assessed in each technique, as well as clinical outcome in all treated lesions. RESULTS: Warm and room temperature trypsinization techniques were comparable with each other. Both were significantly better than the cold technique regarding viability and repigmentation. CONCLUSION: Room temperature trypsinization can be used as a convenient substitute to warm trypsinization. Cold trypsinization is not recommended because of its poor results and poor patient satisfaction.
Subject(s)
Cell Separation/methods , Epidermal Cells/transplantation , Trypsin/metabolism , Ultraviolet Therapy/methods , Vitiligo/therapy , Adolescent , Adult , Cell Survival , Combined Modality Therapy/methods , Epidermal Cells/physiology , Female , Follow-Up Studies , Humans , Male , Middle Aged , Patient Satisfaction , Photography , Prospective Studies , Skin/cytology , Skin/diagnostic imaging , Skin Pigmentation/physiology , Temperature , Transplantation, Autologous/methods , Treatment Outcome , Vitiligo/diagnosis , Young AdultSubject(s)
Facial Dermatoses/diagnosis , Neoplastic Syndromes, Hereditary/diagnosis , Skin Neoplasms/diagnosis , Child , Diagnosis, Differential , Facial Dermatoses/pathology , Facial Dermatoses/surgery , Humans , Male , Neoplastic Syndromes, Hereditary/pathology , Neoplastic Syndromes, Hereditary/surgery , Skin Neoplasms/pathology , Skin Neoplasms/surgerySubject(s)
Lichenoid Eruptions/diagnosis , Sarcoidosis/diagnosis , Skin/pathology , Biopsy , Eyelids , Female , Humans , Lichenoid Eruptions/etiology , Lichenoid Eruptions/pathology , Lymph Nodes/diagnostic imaging , Middle Aged , Sarcoidosis/complications , Sarcoidosis/pathology , Tomography, X-Ray ComputedSubject(s)
Bortezomib/therapeutic use , Dexamethasone/therapeutic use , Hydroxamic Acids/therapeutic use , Indoles/therapeutic use , Multiple Myeloma/drug therapy , Multiple Myeloma/mortality , Neoplasm Recurrence, Local/drug therapy , Adult , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bortezomib/adverse effects , Dexamethasone/adverse effects , Disease-Free Survival , Female , Humans , Hydroxamic Acids/adverse effects , Indoles/adverse effects , Male , Middle Aged , Multiple Myeloma/diagnosis , Neoplasm Invasiveness/pathology , Neoplasm Recurrence, Local/mortality , Neoplasm Recurrence, Local/pathology , Neoplasm Staging , Panobinostat , Practice Guidelines as Topic , Prognosis , Randomized Controlled Trials as Topic , Retreatment/statistics & numerical data , Risk Assessment , Survival Analysis , Treatment Outcome , United KingdomSubject(s)
Antibodies, Monoclonal, Humanized/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/drug therapy , Maytansine/analogs & derivatives , Ado-Trastuzumab Emtansine , Breast Neoplasms/chemistry , Capecitabine/administration & dosage , Cost-Benefit Analysis , Female , Humans , Maytansine/administration & dosage , Practice Guidelines as Topic , Receptor, ErbB-2/analysis , Trastuzumab , United KingdomABSTRACT
Oral erosions and ulcers of pemphigus vulgaris (PV) are a debilitating condition that is usually difficult to treat. The wound healing properties of platelet-rich plasma (PRP) encouraged us to evaluate its usefulness in treatment of non-healing oral PV lesions. Seven patients with chronic oral PV, resistant to conventional therapy, were treated with weekly to monthly injections of PRP of affected mucosal membranes. All recruits reported improvement in pain and mastication and 6 of 7 patients had an improvement in pemphigus disease area index scores with PRP treatment. PRP injections seems to accelerate the healing process and decrease the pain and eating discomfort associated with the oral erosions and ulcers induced by PV.
